PTC Therapeutics, Inc. (NASDAQ: PTCT) director Mary L. Smith executed a significant transaction on July 9, 2026, selling 15,834 shares of common stock. The transaction was valued at approximately $1,425,060, with each share sold at a price of $90.0. This sale price occurred near the stock's 52-week high of $90.87, reflecting the company's recent market momentum. Over the past year, PTCT has delivered a 75% return to investors, though current valuation metrics suggest the stock may be trading above its fair value.
The sale was part of a structured trading activity. Earlier on the same day, Ms. Smith acquired 15,834 shares through the exercise of stock options. These options were exercisable at a price of $42.95 per share, resulting in a total exercise cost of approximately $680,070. The options carried an expiration date of June 10, 2031. Both the acquisition and the subsequent sale were executed pursuant to a pre-arranged Rule 10b5-1 trading plan that Ms. Smith adopted on November 11, 2025. Following these transactions, her direct holding in PTC Therapeutics common stock stands at 21,813 shares.
PTC Therapeutics recently reported financial results for the first quarter of 2026 that exceeded analyst expectations. The company posted an earnings per share of -$0.03, which significantly outperformed the projected -$0.46. Revenue for the quarter reached $273 million, surpassing the anticipated $224.08 million. These financial figures contribute to the company's "GOOD" financial health score, despite ongoing profitability challenges.
Analyst sentiment surrounding PTC Therapeutics has shifted positively following the earnings report. Jefferies upgraded the stock to a Buy rating, citing the promising outlook for Sephience and raising its price target to $85. TD Cowen also upgraded the stock to Buy, highlighting the successful launch of Sephience and improvements in operational efficiency, with a new price target of $90. BofA Securities reiterated its Buy rating, maintaining a $93 price target and expressing confidence in Sephience's potential to achieve global peak sales exceeding $2 billion.
Despite the positive analyst coverage and strong earnings, valuation concerns persist. InvestingPro analysis indicates that PTCT is currently overvalued relative to its fair value, suggesting that the recent price momentum may not be fully supported by underlying valuation models. Investors are encouraged to review the company's valuation and performance metrics to assess the sustainability of its current trajectory.